First AD

Second AD

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Immunotherapy in Lung Cancer

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice

Peer Exchange

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial

The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC

Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors

CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

The Exciting Future of NSCLC Treatment

Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?

POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations

Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations 

Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations 

Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations 